X

Trial Profile

A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Vixtimotamab (Primary) ; Vixtimotamab (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Amphivena Therapeutics

Most Recent Events

11 Oct 2021 Status changed from active, no longer recruiting to completed.
06 Dec 2020 According to an Amphivena Therapeutics media release, data from this study were presented at the 62nd Annual American Society of Hematology Meeting and Exposition (ASH 2020).
21 May 2020 Planned End Date changed from 20 Dec 2021 to 21 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com